alexa DEXTROAMPHETAMINE SULFATE PROVIDES MARKED IMPROVEMENT FOR PATIENTS SUFFERING FROM CHRONIC FATIGUE EVEN WHEN THE ETIOLOGY IS UNEXPLAINED
ISSN: 2165-7386

Journal of Palliative Care & Medicine
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

3rd International Conference on Palliative Care & Hospice Nursing
June 21- 22, 2017 | Philadelphia, USA

Diane Check, Brittney Katsoff, Jerome H Check, Rachael Cohen and Deanna Greco
Cooper Medical School of Rowan University, USA
Vitas Healthcare: Hospice and Palliative Care, USA
ScientificTracks Abstracts: J Palliat Care Med
DOI: 10.4172/2165-7386-C1-008
Abstract
Statement of problem: Dextroamphetamine sulfate is an approved drug for chronic fatigue associated with cancer and multiple sclerosis. The question that the present study was designed to answer is whether the sympathomimetic amine therapy only helps chronic fatigue associated with cancer, and multiple sclerosis, or could it be used in patients in apparent good health but plagued by severe unexplained chronic fatigue. Methods: Dextroamphetamine sulfate extended release capsules were administered to 50 patients with unexplained chronic fatigue (thyroid, adrenal, infectious and autoimmune etiologies excluded). The dosage could be increased on a monthly basis to a maximum of 60mg/day. Six months following the final dosage the patients answered a questionnaire: fatigue – 1) worse, 2) stable but no better, 3) slightly better, 4) moderately better, 5) markedly better. Results: Forty-eight of 50 patients (96%) stated markedly better and 2 patients moderately better. Conclusions: Dextroamphetamine sulfate not only improves the chronic fatigue for patients with cancer and multiple sclerosis, but also very effective relieves chronic fatigue in otherwise physically normal patients. Thus, this study will hopefully encourage palliative care specialists to consider this treatment for chronic fatigue for other debilitating conditions besides cancer and multiple sclerosis. Furthermore, through approved for chronic fatigue for cancer patients, the drug is likely underutilized by palliative care specialists for patients with cancer. Hopefully this study will generate more interest in treating patients with cancer with dextroamphetamine sulfate. The mechanism is likely related to stimulating the release of dopamine from sympathetic nerve fibers. Dopamine decreases cellular permeability and it has been hypothesized that chemicals permeating into mitochondria may cause dysfunction of the mitochondria in muscles leading to fatigue.
Biography

Email: [email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords